Stock Events

Stock Events

Alnylam Pharmaceuticals 

$303
174
+$1.89+0.63% Wednesday 20:00

Statistics

Day High
306.03
Day Low
298.96
52W High
491.22
52W Low
251.15
Volume
1,012,314
Avg. Volume
-
Mkt Cap
40.18B
P/E Ratio
74.59
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.89
0.02
0.93
1.84
Expected EPS
1.60619
Actual EPS
N/A

Financials

8.45%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
7.43BRevenue
627.49MNet Income

Analyst Ratings

442.64Average Price Target
The highest estimate is 527.00.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
71%
Hold
29%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALNY. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals competes directly with Alnylam in the development of RNA-targeted therapies.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.48B
Arrowhead Pharmaceuticals is a direct competitor in RNA interference (RNAi) therapeutics, similar to Alnylam's core technology.
Moderna
MRNA
Mkt Cap17.99B
Moderna, Inc. competes in the broader RNA space with its mRNA technology, which can be seen as complementary or competitive to Alnylam's RNAi.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical competes with Alnylam in the rare disease space, particularly in treatments that could overlap with Alnylam's patient populations.
Sarepta Therapeutics
SRPT
Mkt Cap2.27B
Sarepta Therapeutics, focusing on RNA-based therapies, particularly for rare diseases, competes for similar patient populations and therapeutic areas as Alnylam.
Novartis
NVS
Mkt Cap279.67B
Novartis AG has a broad interest in RNA-based therapies and has been involved in collaborations and competition in the RNA space, including areas Alnylam is targeting.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a diverse portfolio that includes investments in RNA therapies and rare diseases, making it a competitor on multiple fronts.

About

There is no Profile data available for DUL.SG.
Show more...
CEO
Dr. Yvonne L. Greenstreet M.B.A., M.D.
Employees
2230
Country
United States
ISIN
US02043Q1076

Listings

MI
IT
1ALNY.MI
MU
DE
DUL.MU
STU
DE
DUL.STU
LSE
GB
0HD2.LSE

0 Comments

Share your thoughts

FAQ

What is Alnylam Pharmaceuticals stock price today?▼
The current price of ALNY is $303 USD — it has increased by +0.63% in the past 24 hours. Watch Alnylam Pharmaceuticals stock price performance more closely on the chart.
What is Alnylam Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alnylam Pharmaceuticals stocks are traded under the ticker ALNY.
Is Alnylam Pharmaceuticals stock price growing?▼
ALNY stock has fallen by -2.1% compared to the previous week, the month change is a -5.17% fall, over the last year Alnylam Pharmaceuticals has showed a +9.56% increase.
What is Alnylam Pharmaceuticals market cap?▼
Today Alnylam Pharmaceuticals has the market capitalization of 40.18B
When is the next Alnylam Pharmaceuticals earnings date?▼
Alnylam Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What were Alnylam Pharmaceuticals earnings last quarter?▼
ALNY earnings for the last quarter are 1.51 USD per share, whereas the estimation was 0.87 USD resulting in a +73.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alnylam Pharmaceuticals revenue for the last year?▼
Alnylam Pharmaceuticals revenue for the last year amounts to 7.43B USD.
What is Alnylam Pharmaceuticals net income for the last year?▼
ALNY net income for the last year is 627.49M USD.
How many employees does Alnylam Pharmaceuticals have?▼
As of May 07, 2026, the company has 2,230 employees.
In which sector is Alnylam Pharmaceuticals located?▼
Alnylam Pharmaceuticals operates in the Health & Wellness sector.
When did Alnylam Pharmaceuticals complete a stock split?▼
Alnylam Pharmaceuticals has not had any recent stock splits.
Where is Alnylam Pharmaceuticals headquartered?▼
Alnylam Pharmaceuticals is headquartered in Cambridge, United States.